Who is Online

We have 238 guests and no members online

On the road to Damascus

As the years went by I began to doubt the doomsday predictions that accompany the death of each old business, some of which predictions I helped to draft, and to value our economy’s ability to take up new ideas quickly and to quickly abandon those that have had their day. But at some point, like Paul on the road to Damascus, I had an epiphany, realising that our intervention was, in many cases, doing more economic harm than good.

I have spent many long hours debating these issues.  My argument became that we should redirect government support for manufacturing to the area where it demonstrably improves productivity:  to programs that develop skills in, or provide external expertise to, medium sized enterprises that are demonstrating high growth; to foster growth that is reflective of an innovative product or service and/or improved production technology and/or a new market opportunity.  Assistance should not be squandered keeping 'typewriter manufactures' in business or in relocating businesses to a struggling country town where they can only continue to exist on subsidies.

But as we are presently witnessing, politicians like to offer their electorate taxpayer funded presents. And they feel a need to do or, more often, just to say something in mitigation, if a significant business is to be lost.  They often expect to be backed-up with some kind of executive action, usually amounting to a taxpayer handout, to delay a closure.

I could easily list another twenty major manufacturing closures in regional NSW, including iron and steel making in Newcastle, and probably, if I had access to the database, thousands of smaller businesses, where there is a high ‘churn rate’ of start-ups and closures.

I have come to accept that these many closures have not devastated the Australian economy.  Quite the opposite - resources have been redistributed more efficiently.  The economy grew rapidly at the end of the last century as we began to concentrate on the things we do well and to abandon those old industries that once weighed us down. 

History shows that the impact of such a closure is often ultimately beneficial.  The decision to abandon a moribund, unprofitable industry in a growing city can be positive, as productive resources, including land; factory space; and skilled people, are rearranged. 

On my birthday in 1999, Newcastle, that was once the home of Australia's largest steel maker with a peak workforce of almost 12,000, saw the closure of the coke ovens,  blast furnaces, and steelmaking that once defined the city.  In a decade and a half since the closure, Newcastle has blossomed and now has a larger workforce; a larger population; and substantially lower unemployment; than it had in 1999.

But for me, the last step on the road to Damascus was the Victorian Government’s attempts to save a Kodak processing plant at Burnley, in the face of obvious technological change.  It became a symbol of wrong headedness.  How could anyone not see that film was a dying, if not already dead, technology?  That they enlisted Federal support for this farrago was unconscionable.  Australian taxpayers money, that could have been spent on scientific research;  education;  infrastructure; or dozens of better projects that could be real investments in the future, was squandered. 

 

 

No comments

Travel

Berlin

 

 

 

I'm a bit daunted writing about Berlin.  

Somehow I'm happy to put down a couple of paragraphs about many other cities and towns I've visited but there are some that seem too complicated for a quick 'off the cuff' summary.  Sydney of course, my present home town, and past home towns like New York and London.  I know just too much about them for a glib first impression.

Although I've never lived there I've visited Berlin on several occasions for periods of up to a couple of weeks.  I also have family there and have been introduced to their circle of friends.

So I decided that I can't really sum Berlin up, any more that I can sum up London or New York, so instead I should pick some aspects of uniqueness to highlight. 

Read more: Berlin

Fiction, Recollections & News

The Password

 

 

 

 

How I miss Rio.  Rio de Janeiro the most stunningly picturesque city on Earth with its dark green mountains and generous bays, embelezado with broad white, sandy beaches.  Rio forever in my heart.   Rio my a minha pátria, my homeland, where I spent the most wonderful days of my life with linda, linda mãe, my beautiful, beautiful mother. Clambering up Corcovado Mountain together, to our favela amongst the trees.

Thinking back, I realise that she was not much older than I was, maybe fifteen years.  Who knows?

Her greatest gift to me was English. 

Read more: The Password

Opinions and Philosophy

The race for a SARS-CoV-2 vaccine

 

 

 

 

As we all now know (unless we've been living under a rock) the only way of defeating a pandemic is to achieve 'herd immunity' for the community at large; while strictly quarantining the most vulnerable.

Herd immunity can be achieved by most people in a community catching a virus and suffering the consequences or by vaccination.

It's over two centuries since Edward Jenner used cowpox to 'vaccinate' (from 'vacca' - Latin for cow) against smallpox. Since then medical science has been developing ways to pre-warn our immune systems of potentially harmful viruses using 'vaccines'.

In the last fifty years herd immunity has successfully been achieved against many viruses using vaccination and the race is on to achieve the same against SARS-CoV-2 (Covid-19).

Developing; manufacturing; and distributing a vaccine is at the leading edge of our scientific capabilities and knowledge and is a highly skilled; technologically advanced; and expensive undertaking. Yet the rewards are potentially great, when the economic and societal consequences of the current pandemic are dire and governments around the world are desperate for a solution. 

So elite researchers on every continent have joined the race with 51 vaccines now in clinical trials on humans and at least 75 in preclinical trials on animals.

Read more: The race for a SARS-CoV-2 vaccine

Terms of Use

Terms of Use                                                                    Copyright